MET Inhibition in Clear Cell Renal Cell Carcinoma

Background: Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer. Small molecule VEGFR inhibitors are widely used but are not curative and various resistance mechanisms such as activation of the MET pathway have been described. Dual MET/VEGFR2 inhibitors have recently sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Zuoquan, Lee, Young H., Boeke, Marta, Jilaveanu, Lucia B., Liu, Zongzhi, Bottaro, Donald P., Kluger, Harriet M., Shuch, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934028/
https://www.ncbi.nlm.nih.gov/pubmed/27390595
http://dx.doi.org/10.7150/jca.14604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934028/
https://www.ncbi.nlm.nih.gov/pubmed/27390595
http://dx.doi.org/10.7150/jca.14604

Ejemplares similares